Ganglioside treatment of genetic and alloxan-induced diabetic neuropathy

Related Experiment Video

Updated: Oct 21, 2026

Neo-Islet Formation in Liver of Diabetic Mice by Helper-dependent Adenoviral Vector-Mediated Gene Transfer
16:59

Neo-Islet Formation in Liver of Diabetic Mice by Helper-dependent Adenoviral Vector-Mediated Gene Transfer

Published on: October 10, 2012

A Gorio, F Aporti, F Di Gregorio

    Advances in Experimental Medicine and Biology
    |January 1, 1984
    PubMed

    Insights

    Gangliosides effectively treat diabetic neuropathy in mice and rats, improving nerve function and sensory perception even at later disease stages. This suggests gangliosides offer a therapeutic advantage over insulin when neuropathy progresses.

    Area of Science:

    • Neuroscience
    • Diabetology
    • Pharmacology

    Background:

    • Diabetic peripheral neuropathy is a common and debilitating complication of diabetes mellitus.
    • Early stages may respond to metabolic control, but advanced neuropathy often shows limited response to insulin.
    • Understanding the progression and therapeutic targets is crucial for effective treatment.

    Purpose of the Study:

    • To investigate the development of diabetic peripheral neuropathy in mouse and rat models.
    • To evaluate the efficacy of ganglioside treatment in different stages of diabetic neuropathy.
    • To compare the therapeutic effects of gangliosides and insulin.

    Main Methods:

    • Utilized mutant diabetic mice (C57BL/ks db/db) and alloxan-induced diabetic rats.
    • Assessed nerve conduction velocity (NCV), slow axonal transport, and myelin particle density.
    • Administered insulin and gangliosides at various time points post-diabetes induction.

    Main Results:

    • Db/db mice showed reduced NCV early on, with impaired slow transport and myelin density later.
    • Insulin improved NCV in early stages but lost efficacy in advanced neuropathy.
    • Gangliosides improved NCV, myelin density, and auditory function in advanced diabetic neuropathy.

    Conclusions:

    • Diabetic neuropathy progression involves a shift from a metabolic to a neuronal stage.
    • Gangliosides demonstrate therapeutic efficacy in advanced diabetic neuropathy where insulin is less effective.
    • Gangliosides represent a promising treatment for diabetic peripheral neuropathy, particularly in later stages.

    More Related Videos

    Adenoviral Gene Therapy for Diabetic Keratopathy: Effects on Wound Healing and Stem Cell Marker Expression in Human Organ-cultured Corneas and Limbal Epithelial Cells11:13

    Adenoviral Gene Therapy for Diabetic Keratopathy: Effects on Wound Healing and Stem Cell Marker Expression in Human Organ-cultured Corneas and Limbal Epithelial Cells

    Published on: April 7, 2016

    Ganglioside Extraction, Purification and Profiling10:05

    Ganglioside Extraction, Purification and Profiling

    Published on: March 12, 2021

    Related Concept Videos

    Oral Hypoglycemic Agents: Glinides01:06

    Oral Hypoglycemic Agents: Glinides

    Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
    Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

    Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

    α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
    Acarbose and miglitol are typically...
    Glucagon-like Receptor Agonists01:24

    Glucagon-like Receptor Agonists

    Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
    GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
    Type I Diabetes II: Pathophysiology01:26

    Type I Diabetes II: Pathophysiology

    Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
    Diabetic Neuropathy01:22

    Diabetic Neuropathy

    DefinitionDiabetic neuropathy is nerve damage caused by long-standing diabetes mellitus. It results directly from prolonged high blood sugar levels.PathophysiologyThe pathophysiology of diabetic neuropathy involves both metabolic and vascular disturbances triggered by chronic hyperglycemia.Metabolic injury: Elevated glucose levels activate the polyol pathway within nerve cells, leading to the accumulation of sorbitol and fructose. This increases oxidative stress, disrupts normal nerve...